Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported Research And Development Expense of $106.24 million for the year ending 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed a decrease of -2.4% in Research And Development Expense from 2024 to 2025.
- This data is from SUPERNUS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: $7.45 million | Q2 2011: $7.25 million | Q3 2011: $8.43 million | Q1 2012: $5.36 million | Q2 2012: $4.70 million | Q3 2012: $8.31 million | Q1 2013: $4.52 million | Q2 2013: $3.54 million | Q3 2013: $3.78 million | Q1 2014: $4.48 million | Q2 2014: $4.68 million | Q3 2014: $4.66 million | Q1 2015: $3.68 million | Q2 2015: $6.88 million | Q3 2015: $9.13 million | Q1 2016: $10.56 million | Q2 2016: $11.11 million | Q3 2016: $7.87 million | Q1 2017: $9.60 million | Q2 2017: $10.82 million | Q3 2017: $12.98 million | Q1 2018: $18.91 million | Q2 2018: $20.04 million | Q3 2018: $20.42 million | Q1 2019: $15.39 million | Q2 2019: $16.97 million | Q3 2019: $16.94 million | Q1 2020: $18.94 million | Q2 2020: $22.25 million | Q3 2020: $16.84 million | Q1 2021: $34.28 million | Q2 2021: $15.46 million | Q3 2021: $19.65 million | Q1 2022: $20.84 million | Q2 2022: $16.39 million | Q3 2022: $19.55 million | Q1 2023: $21.21 million | Q2 2023: $24.38 million | Q3 2023: $22.66 million | Q1 2024: $24.93 million | Q2 2024: $26.18 million | Q3 2024: $29.04 million | Q1 2025: $26.93 million | Q2 2025: $22.12 million | Q3 2025: $29.37 million.
- Over the full 16 years of available data (2010 to 2025), SUPERNUS PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 202.2%.
- Historical annual values: Fiscal year 2025: $106.24 million | Fiscal year 2024: $108.80 million | Fiscal year 2023: $91.59 million | Fiscal year 2022: $74.55 million | Fiscal year 2021: $90.47 million | Fiscal year 2020: $75.96 million | Fiscal year 2019: $69.10 million | Fiscal year 2018: $89.21 million | Fiscal year 2017: $49.58 million | Fiscal year 2016: $42.79 million | Fiscal year 2015: $29.14 million | Fiscal year 2014: $19.59 million | Fiscal year 2013: $17.25 million | Fiscal year 2012: $23.52 million | Fiscal year 2011: $30.63 million | Fiscal year 2010: $35.15 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: